Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Construction in Progress (2020 - 2025)

Insight Molecular Diagnostics' Construction in Progress history spans 6 years, with the latest figure at $685000.0 for Q3 2025.

  • For Q3 2025, Construction in Progress rose 126.82% year-over-year to $685000.0; the TTM value through Sep 2025 reached $685000.0, up 126.82%, while the annual FY2024 figure was $340000.0, 53.17% down from the prior year.
  • Construction in Progress for Q3 2025 was $685000.0 at Insight Molecular Diagnostics, up from $263000.0 in the prior quarter.
  • Across five years, Construction in Progress topped out at $3.1 million in Q1 2022 and bottomed at $263000.0 in Q2 2025.
  • The 5-year median for Construction in Progress is $685000.0 (2025), against an average of $1.1 million.
  • The largest annual shift saw Construction in Progress plummeted 85.83% in 2021 before it surged 730.52% in 2022.
  • A 5-year view of Construction in Progress shows it stood at $1.2 million in 2021, then surged by 72.3% to $2.1 million in 2022, then crashed by 66.07% to $726000.0 in 2023, then plummeted by 53.17% to $340000.0 in 2024, then soared by 101.47% to $685000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Construction in Progress are $685000.0 (Q3 2025), $263000.0 (Q2 2025), and $360000.0 (Q1 2025).